These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 29974955)
21. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983 [TBL] [Abstract][Full Text] [Related]
22. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies). ESMO Guidelines Committee Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925 [No Abstract] [Full Text] [Related]
23. Novel agents versus chemotherapy as frontline treatment of CLL. Piggin A; Bayly E; Tam CS Leuk Lymphoma; 2017 Jun; 58(6):1320-1324. PubMed ID: 28271950 [TBL] [Abstract][Full Text] [Related]
24. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy. Wendtner CM Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694 [No Abstract] [Full Text] [Related]
37. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). Godet S; Protin C; Dupuis J; Dartigeas C; Bastie JN; Herbaux C; Leblond V; de Guibert S; Ghez D; Brion A; Ysebaert L; Delmer A; Quinquenel A Am J Hematol; 2018 Feb; 93(2):E52-E54. PubMed ID: 29164674 [No Abstract] [Full Text] [Related]
38. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia. Shah A; Mangaonkar A Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276 [TBL] [Abstract][Full Text] [Related]